Studies Addressing Rare Neurodegenerative Diseases including ALS
Agency: Food and Drug Administration
- 93.103 -- Food and Drug Administration Research
Forecasted opportunityLast Updated: May 13, 2026
Important dates
- Forecasted post date: Not specified
- Forecasted application due date: Not specified
- Forecasted award date: Not specified
- Forecasted project start date: Not specified
- Fiscal Year: 2025
Award details
- Expected project funding: Not specified
- Expected awards: 10
Award min.
Not specified
Award max.
Not specified
- Funding opportunity number:FOR-FD-25-006
- Cost sharing or matching requirement:No
- Funding instrument type:
- Grant
- Opportunity Category:Discretionary
- Opportunity Category Explanation:Not specified
- Category of Funding Activity:
- Consumer protection
- Agriculture
- Food and nutrition
- Category Explanation:Not specified
History
- Forecast posted date: August 14, 2024
- Archive date: Not specified
- Version: 1
Summary
The purpose of this funding opportunity announcement (FOA) is to support studies that advance medical product development of interventions intended to prevent, diagnose, mitigate, treat, or cure ALS and other rare neurodegenerative diseases in adults and children. Through the support of these studies, FDA expects to address critical knowledge gaps, exert a significant impact on rare neurodegenerative diseases, and to inform current or future product development.
Eligibility
Miscellaneous
- Unrestricted
Government
- State governments
- City or township governments
- Public and Indian housing authorities
- County governments
- Special district governments
- Federally recognized Native American tribal governments
Education
- Independent school districts
- Private institutions of higher education
- Public and state institutions of higher education
Nonprofit
- Nonprofits non-higher education with 501(c)(3)
- Nonprofits non-higher education without 501(c)(3)
- Other Native American tribal organizations
Business
- Small businesses
- For-profit organizations other than small businesses
Additional information on eligibility
Documents
No documents are currently available.
Agency contact information
Email: terrin.brown@fda.hhs.gov
terrin.brown@fda.hhs.gov
Link to additional information
No additional information is available
